Survey about brigatinib for ALK-positive lung cancer

This trial is for people with advanced ALK-positive lung cancer who are already taking the targeted therapy brigatinib and have a few remaining spots of cancer. It tests whether adding local treatments (like surgery, focused radiation, or ablation) to the remaining spots can improve outcomes.

This trial tests brigatinib, a targeted pill medicine, in children and young adults with ALK-positive cancers (including ALCL and IMT, plus some other solid tumors). It’s designed to see how well it works and what side effects it causes in people whose tumors have a specific ALK change.

This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.

This study looks at what happens when lung cancer stops responding to the drug lorlatinib, which is used as the first treatment for ALK-positive non-small cell lung cancer. It aims to find out why the drug stops working and what the next best treatment might be, which could help guide future care.

This trial tests a drug called gilteritinib for people with a specific genetic type of lung cancer (ALK-positive) that has spread and has been treated before. You may be eligible if you have already tried at least one targeted therapy, and your cancer is still growing.

This trial tests lorlatinib, a pill that targets a specific genetic change in lung cancer cells (ALK-positive). It may help people with advanced lung cancer who have not yet had treatment for their advanced disease.